Meloxicam Inhibits Hepatocellular Carcinoma Progression and Enhances the Sensitivity of Immunotherapy via the MicroRNA-200/PD-L1 Pathway

BACKGROUND: Hepatocellular carcinoma (HCC) has become the sixth most common cancer and the third leading cause of cancer death in the world. Although the research achievements of tumor immunotherapy have made great progress, especially the combination of immune targeted therapy has achieved good cur...

Descripción completa

Detalles Bibliográficos
Autores principales: Guangshun, Sun, Guoqiang, Sun, Xin, Chen, Xiangyi, Kong, Wubin, Zheng, Zhitao, Li, Zhiying, Zheng, Hongyong, Cao, Chengyu, Lv, Yongxiang, Xia, Weiwei, Tang
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Hindawi 2022
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8885196/
https://www.ncbi.nlm.nih.gov/pubmed/35237322
http://dx.doi.org/10.1155/2022/4598573

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8885196/
https://www.ncbi.nlm.nih.gov/pubmed/35237322
http://dx.doi.org/10.1155/2022/4598573

Ejemplares similares